Non-Hodgkin Lymphoma

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Here are the top 5 CURE stories for July 2019.

Three-time cancer survivor and one-woman show writer and performer, Valerie David, sat down with CURE® to discuss life as a survivor.

This essay describes my journey with non-Hodgkin lymphoma — peripheral T-cell, not otherwise specified — and my most extraordinary nurse, Xuan Arnette, RN, OCN.

From landmark Senate legislation to the Pink Lemonade Stand Challenge, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of certain adult patients with CD20-positive B-cell non-Hodgkin’s lymphoma and those with chronic lymphocytic leukemia.

Outwardly, you start to look like your old self again while inside you're still licking the wounds of your cancer battle.

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

How to conquer the fear of your own body, one step at a time.

WE SURVIVORS ARE INUNDATED with the message: “Be hopeful!” Unfortunately, that universal rallying cry doesn’t help us know how to find hope or what to hope for.

Long-term follow-up of the JULIET trial showed patients with relapsed or refractory DLBCL continued to experience durable responses 19 months after treatment.

Preventing febrile neutropenia is crucial because the body’s white blood cells help to fight infection.